Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011719 · ClinicalTrials.gov registry record · Phase 3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma, sponsored by Arcus Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 20
- Study locations
NCT07011719 is a Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Arcus Biosciences. The registered enrollment target is 720 participants, above the 98-participant average among 13 other Metastatic Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (635% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT07011719, a Phase 3 study of Metastatic Clear Cell Renal Cell Carcinoma and Advanced Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Arcus Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
- DRUG Casdatifan
Study Locations (20)
California
- City Of Hope National Medical Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- UCLA Hematology Oncology - 100 Med Plaza - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
Georgia
- Piedmont Cancer Institute OneOncology - Atlanta
- Emory University - Atlanta - Atlanta
- City of Hope Cancer Center Atlanta - Newnan
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic Foundation - Cleveland
- University Hospitals Cleveland Medical Center - Cleveland
Arizona
- City of Hope - Phoenix Cancer Center - Goodyear
Connecticut
- Yale University - New Haven
Illinois
- City of Hope - Chicago Cancer Center - Zion
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011719
The ClinicalTrials.gov registry entry for NCT07011719 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 13 other Metastatic Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (635% higher). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07011719 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07011719 about?
NCT07011719 is a clinical study titled "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma". The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti...
What is the current status of trial NCT07011719?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2025-09-08. Estimated completion is 2030-12.
What conditions does trial NCT07011719 study?
This clinical trial studies the following conditions: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT07011719?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG), Casdatifan (DRUG).
Who is sponsoring clinical trial NCT07011719?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011719 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RECRUITING · Phase 3
-
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RECRUITING
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
RECRUITING · Phase 1
-
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Advanced Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.